Description:
* "BLIS
is an acronym for Bacteriocin Like Inhibitory Substances. Certain strains
of micro-organisms produce BLIS substances, which act as natural
antibiotics and control the growth of undesirable bacterial infections.
The Company was formed in June 2000 to pursue the commercialisation of
BLIS bacteriocin-like inhibitory substances. These are antibacterial
peptides or proteins that are able to kill or control the growth of other
closely related bacteria. The first such substance which the Company has
developed is from a micro-organism called Streptococcus salivarius, which
produces an antibacterial protein named Salivaricin B. Salivaricin B is a
BLIS, hence the Company's name BLIS Technologies Limited.
BLIS Technologies Limited acquired from Otago University of New Zealand, the extensive collection of BLIS producing organisms gathered by Professor John Tagg over a 20 year period."
Website: http://www.blis.co.nz/
Recent announcements: click here
|
Year |
|
|
|
2005 |
2006 |
|
|
|
Gross
growth rates |
|
|
|
|
|||
|
Revenue |
|
|
|
|
12% |
|
|
|
NPAT |
|
|
|
|
-17% |
|
|
|
Total
Assets |
|
|
|
|
-49% |
|
|
|
Net
Assets |
|
|
|
|
-60% |
|
|
|
Per
Share figures and growth |
|||||||
|
Earnings |
|
|
|
$
(0.01) |
$
(0.01) |
|
|
|
|
|
|
|
|
-17% |
|
|
|
Net
Assets |
|
|
|
$
0.02 |
$
0.01 |
|
|
|
|
|
|
|
|
-60% |
|
|
|
Dividends |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profitability |
|||||||
|
Return
on Assets |
|
|
|
-66.74% |
-107.45% |
|
|
|
Equity
Multiplier |
|
|
|
1.09 |
1.42 |
|
|
|
Return
on Equity (ROE) |
|
|
|
-73% |
-152% |
|
|
|
ROE
(avg E) |
|
|
|
-146% |
-86% |
|
|
|
Net
Profit Margin |
|
|
|
-257% |
-190% |
|
|
|
Dividend
payout ratio |
|
|
|
0% |
0% |
|
|
|
Liquidity |
|||||||
|
Net
working capital |
|
|
|
$1,303,244
|
$270,084
|
|
|
|
Current
ratio |
|
|
|
8.80 |
1.89 |
|
|
|
Acid
test ratio |
|
|
|
7.67 |
1.09 |
|
|
|
Other |
|||||||
|
Times
interest earned |
|
|
|
|
|
|
|
|
Operating
exp/income |
|
|
|
357% |
290% |
|
|
|
|
|
|
|
|
|
|
|
|
Summary
Financials |
|||||||
|
Income |
|
|
|
520393 |
583033 |
|
|
|
Expenses |
|
|
|
1856712 |
1690884 |
|
|
|
Tax |
|
|
|
0 |
0 |
|
|
|
NPAT |
|
|
|
-1336319 |
-1107851 |
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
2002243 |
1031048 |
|
|
|
Liabilities |
|
|
|
167143 |
303799 |
|
|
|
Net
Assets |
|
|
|
1835100 |
727249 |
|
|
| Registered Office: |
Mailing address: |
| Directors: Colin Ernest Dawson Peter Francis Fennessy Maxwell Gilbert Shepherd |
Secretary: |
| Auditors: Deloitte |
Solicitors: Anderson Lloyd Caudwell |
| Bankers: |
Registrar: |
| Other: |
|
Gain access to professional equity research reports
| Other | Last updated:14-11-2007 |
Company balance date: 31 March
Trading over the last year
